Clinical Trial

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a multicenter, single-arm, phase II clincial trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (sac-TMT) and Furmonertinib in the treatment of EGFR-mutant advanced or metastatic NSCLC after failure of first-line Third-generation EGFR-TKI therapy.
Trial Details
NCT Number NCT07193160
Lead Sponsor Fudan University
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 45 participants
Start Date 2025-11-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-25